Table II. Caspases direct constitutive and Fas-induced proplatelet formation.
| Proplatelet MKs per 2 × 105 MKs
|
||
|---|---|---|
| Condition | Constitutive | CH11 induced |
| Control | 1,340 ± 147 | 7,930 ± 923 |
| zVAD-fmk (10 μM) | 82 ± 36a | 245 ± 47a |
| zDEVD-fmk (10 μM) | 227 ± 55a | 990 ± 247a |
| zIETD-fmk (10 μM) | 699 ± 97a | 536 ± 103a |
| BioPORTER® control | 1,516 ± 48 | 4,756 ± 372 |
| BioPORTER® crmA | 1,387 ± 156 | 2,396 ± 240b |
| BioPORTER® HI crmA | ND | 4,400 ± 500 |
| BioPORTER® active caspase-8 | 2,502 ± 368b | ND |
Proplatelet MK count represents total number of proplatelet-bearing MKs following 8 h of culture, scored by phase microscopy. zDEVD-fmk has enhanced specificity over zVAD-fmk as a caspase-3 inhibitor. HI, heat inactivated; Data represent mean ± SD of a minimum of three determinations.
a
P < 0.01 compared to control.
b
P < 0.01 compared to BioPORTER® control.